乳腺癌Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapy Type (Targeted therapy, Chemotherapy, Surgery & Radiation Therapy, Hormonal therapy); By Region, Segments & Forecast, 2018 - 2026

Table of Contents

1. Overview and Scope
   1. Research goal & scope
   2. Research assumptions
   3. Research Methodology
      1. Primary data sources
      2. Secondary data sources
   4. Key take-away
   5. Stakeholders
2. 执行概要
   1. Market Definition
   2. Market Segmentation
3. 乳腺癌Therapies Market Insights
   1. 乳腺癌Therapies – Industry snapshot
   2. 乳腺癌Therapies - Ecosystem analysis
   3. 乳腺癌Therapies Market Dynamics
      1. 乳腺癌Therapies – Market Forces
         1. 乳腺癌Therapies Market Driver Analysis
         2. 乳腺癌Therapies Market Restraint/Challenges analysis
         3. 乳腺癌Therapies Market Opportunity Analysis
   4. Industry analysis - Porter's five force
      1. Bargaining power of supplier
      2. Bargaining power of buyer
      3. Threat of substitute
      4. Threat of new entrant
      5. Degree of competition
   5. 乳腺癌Therapies Market PEST Analysis, 2017
   6. 乳腺癌Therapies Market Value Chain Analysis
   7. 乳腺癌Therapies Industry Trends
   8. Competitive Ranking Analysis
4. 乳腺癌Therapies Market Size and Forecast, 2017-2026 by Therapy type
   1. Key Findings
   2. Targeted therapy
   3. Chemotherapy
   4. Surgery & radiation therapy
   5. Hormonal therapy
5. 乳腺癌Therapies Market Size and Forecast, 2017-2026 by Region
   1. Key Findings
   2. North America
      1. U.S.
      2. Canada
   3. Europe
      1. Germany
      2. UK
      3. France
   4. Asia-Pacific
      1. China
      2. India
      3. Japan
   5. Latin America
      1. Brazil
   6. Middle East & Africa
6. Company Profiles
   1. AstraZeneca, Bayer AG
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   2. Danaher
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   3. Bristol Myers Squibb
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   4. Eisai Co., Ltd.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   5. Merck & Co.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   6. Novartis AG
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   7. Novocure
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   8. Pfizer Inc.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
   9. Hoffmann-La Roche AG
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments